Present disclose provides a kind of reduction serum cholesterol and triglyceride levels objects. These compositions can contain racemic beta-hydroxybutyrate or D- beta-hydroxy-butanoic acid salt, optionally in sour form, the salt racemic beta-hydroxybutyrate or D- beta-hydroxy-butanoic acid salt esters of physical compatibility, D- beta-hydroxy-butanoic acid salt, the monomeric unit that D- beta-hydroxy-butanoic acid salt in oligomer contains from 2 to 20 or more is in linear or annular form, racemic 1,3 butanediols or R- 1,3 butanediols individually optionally, are administered to patient in conjunction with low fat diet. In addition, composition includes racemic beta-hydroxybutyrate or D- beta-hydroxy-butanoic acid salt, optionally in sour form, the salt racemic beta-hydroxybutyrate or D- beta-hydroxy-butanoic acid salt esters of physical compatibility, D- beta-hydroxy-butanoic acid salt, the monomeric unit that D- beta-hydroxy-butanoic acid salt in oligomer contains from 2 to 20 or more is in linear or annular form, racemic 1,3 butanediols, R- 1,3 butanediol esters or combinations thereof can be configured to nutritional additive (also referred to as trophic component) or be merged into therapeutic composition, include a) anti-hypertensive agent Step b) anti-inflammatory agents Step c) reduces the reagent of glucose D) anti-lipemic agent), these patients administration, optionally and low fat diet, so as to cause mitigating or reducing: serum cholesterol level Triglyceride level Serum glucose level, the object of Serum Homocysteine Level, inflammatory protein (for example, c reactive protein) and/or hypertension therapeutic. In addition, disclosed composition can be administered alone or what other therapeutic agents combined prevents or reverse vascular diseases.
